Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.30 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28666452 | 0.87 | — | — | |
| SCHEMBL25848538 | 0.86 | SMN1; SMN2 (0.55) | SMN1; SMN2LMNAALDH1A1TSHRHSD17B10 | |
| SCHEMBL12770278 | 0.84 | — | — | |
| SCHEMBL2608053 | 0.82 | SMN1; SMN2 (0.30) | SMN1; SMN2 | |
| SCHEMBL20128921 | 0.82 | — | — | |
| SCHEMBL23015199 | 0.82 | LMNA (0.62) | SMN1; SMN2LMNAALDH1A1TSHRHSD17B10 | |
| SCHEMBL14831463 | 0.82 | LMNA (0.62) | SMN1; SMN2LMNAALDH1A1TSHRHSD17B10 | |
| SCHEMBL16845302 | 0.82 | LMNA (0.62) | SMN1; SMN2LMNAALDH1A1TSHRHSD17B10 | |
| SCHEMBL14830449 | 0.82 | LMNA (0.62) | SMN1; SMN2LMNAALDH1A1TSHRHSD17B10 | |
| SCHEMBL21398806 | 0.80 | ALDH1A1 (0.31) | SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702396-B2 | Hydrophobic compounds for optically active devices | Johnson & Johnson Surgical Vision, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702396-B2 | Hydrophobic compounds for optically active devices | Johnson & Johnson Surgical Vision, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11014901-B2 | Hydrophobic compounds for optically active devices | MERCK PATENT GMBH (DE) | 2021-05-25 | — | — | US | disclosed |
| US-11001576-B2 | Compounds for optically active devices | MERCK PATENT GMBH (DE) | 2021-05-11 | — | — | US | disclosed |
| EP-3583091-B1 | HYDROPHOBIC COMPOUNDS FOR OPTICALLY ACTIVE DEVICES | MERCK PATENT GMBH (DE) | 2020-11-04 | — | — | EP | disclosed |
| EP-3583102-B1 | HYDROPHOBIC COMPOUNDS FOR OPTICALLY ACTIVE DEVICES | MERCK PATENT GMBH (DE) | 2020-11-04 | — | — | EP | disclosed |
| EP-3583101-B1 | BIS-COMPOUNDS FOR OPTICALLY ACTIVE DEVICES | MERCK PATENT GMBH (DE) | 2020-10-28 | — | — | EP | disclosed |
| US-20200062739-A1 | COMPOUNDS FOR OPTICALLY ACTIVE DEVICES | MERCK PATENT GMBH (DE) | 2020-02-27 | — | — | US | disclosed |
| US-20200055833-A1 | HYDROPHOBIC COMPOUNDS FOR OPTICALLY ACTIVE DEVICES | MERCK PATENT GMBH (DE) | 2020-02-20 | — | — | US | disclosed |
| EP-1244648-B1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | GENZYME CORP (US) | 2009-04-15 | — | — | EP | disclosed |
| EP-1244648-B1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | GENZYME CORP (US) | 2009-04-15 | — | — | EP | disclosed |
| US-20070060591-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2007-03-15 | — | — | US | disclosed |
| US-20070060591-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2007-03-15 | — | — | US | disclosed |
| US-7022717-B2 | Chemokine receptor binding heterocyclic compounds | ANORMED, INC. (CA) | 2006-04-04 | — | — | US | disclosed |
| US-20060069129-A1 | Chemokine receptor binding heterocyclic compounds | BRIDGER GARY J | 2006-03-30 | — | — | US | disclosed |
| US-20040102428-A1 | Chemokine receptor binding heterocyclic compounds | ANORMED CORPORATION (CA) | 2004-05-27 | — | — | US | disclosed |
| US-6667320-B2 | For therapy of infalmmation; asthma, cancer, arthritis, multiple sclerosis; prophylaxis of infection of target cells by a human immunodeficiency virus (HIV) | ANORMED (CA) | 2003-12-23 | — | — | US | disclosed |
| EP-1244648-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2002-10-02 | — | — | EP | disclosed |
| US-20020077339-A1 | Chemokine receptor binding heterocyclic compounds | ANORMED CORPORATION (CA) | 2002-06-20 | — | — | US | disclosed |
| WO-2001044229-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2001-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060591-A1 | Chemokine receptor binding heterocyclic compounds | CCR5, ACKR3, CCR2 | SMN1; SMN2 4072/4885LMNA 4528/4885ALDH1A1 3141/4885 |
| US-20200055833-A1 | HYDROPHOBIC COMPOUNDS FOR OPTICALLY ACTIVE DEVICES | UACA, CRYZ, TRPA1 | SMN1; SMN2 4872/4885LMNA 2186/4885ALDH1A1 1851/4885 |
| US-20040102428-A1 | Chemokine receptor binding heterocyclic compounds | CCR5, ACKR3, CCR2 | SMN1; SMN2 4072/4885LMNA 4528/4885ALDH1A1 3141/4885 |
| US-11702396-B2 | Hydrophobic compounds for optically active devices | UACA, CRYZ, TRPA1 | SMN1; SMN2 4872/4885LMNA 2186/4885ALDH1A1 1851/4885 |
| US-20200062739-A1 | COMPOUNDS FOR OPTICALLY ACTIVE DEVICES | PDE6C, PDE6A, PDE6D | SMN1; SMN2 4710/4885LMNA 3299/4885ALDH1A1 388/4885 |
| US-20020077339-A1 | Chemokine receptor binding heterocyclic compounds | CCR5, ACKR3, CCR2 | SMN1; SMN2 4072/4885LMNA 4528/4885ALDH1A1 3141/4885 |
| US-20060069129-A1 | Chemokine receptor binding heterocyclic compounds | CCR5, ACKR3, CCR2 | SMN1; SMN2 4072/4885LMNA 4528/4885ALDH1A1 3141/4885 |
| US-11001576-B2 | Compounds for optically active devices | PDE6C, PDE6A, PDE6D | SMN1; SMN2 4710/4885LMNA 3299/4885ALDH1A1 388/4885 |
| US-11014901-B2 | Hydrophobic compounds for optically active devices | UACA, CRYZ, TRPA1 | SMN1; SMN2 4872/4885LMNA 2186/4885ALDH1A1 1851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.